ArticleSurgical endoscopy2026
The application value of Da Vinci linear powered stapler SureForm in robotic sphincter-preserving surgery for rectal cancer: a prospective randomized clinical trial.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAnastomotic leakage remains a major complication after robotic low anterior resection for rectal cancer. Technological advancements in stapling devices may influence clinical outcomes. This study aimed to evaluate whether the novel da Vinci SureForm robotic linear stapler reduces anastomotic complications compared with conventional articulating laparoscopic staplers.
methodsThis single-center, prospective randomized clinical trial was conducted from December 30, 2022, to December 20, 2024. A total of 276 patients with rectal cancer scheduled for robotic sphincter-preserving anterior resection were randomly assigned to undergo rectal transection and anastomosis using either the da Vinci SureForm robotic linear stapler (intervention group) or conventional laparoscopic articulating linear staplers (control group). The primary outcome was the 30-day incidence of anastomotic leakage.
resultsThe intervention group had a lower incidence of anastomotic leakage than the control group (6.67 vs. 14.07%, P=0.046), and this trend was also evident for severe cases (Clavien-Dindo grade ≥ II: 1.48 vs. 6.67%, P=0.031). Intention-to-treat analysis suggested a lower leakage rate in the intervention group (6.57 vs. 14.39%, P=0.034). The number of linear stapler cartridges required for rectal transection was lower in the intervention group (1.95±0.67 vs. 2.32±0.85, P<0.001), and the rate of using ≥3 cartridges was also lower (18.50 vs. 37.00%, P<0.001). Multivariate analysis identified stapler cartridges >2 (P=0.002), tumor location (P<0.001), and anastomotic hemorrhage (P=0.013) as independent risk factors for anastomotic leakage.
conclusionsThe novel da Vinci SureForm linear powered stapler demonstrated a favorable safety profile with a potentially lower incidence of anastomotic leakage and reduced cartridge requirements compared with conventional staplers in robotic sphincter-preserving surgery for rectal cancer.
Indexed as
Identifiers
42745051What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.